Using pro-apoptotic drugs to improve treatments for pulmonary tuberculosis
Official title: Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis
Funded at Johns Hopkins University · NIH-11125008 · Data updated 2026-11-12
This study is looking at a new drug called navitoclax to see if it can help people with pulmonary tuberculosis (TB) by helping their bodies get rid of infected cells, which could lead to faster recovery and less damage to the lungs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $817,941 |
| NIH project number | 1R56AI179012-01A1 |
| Project ID | NIH-11125008 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with pulmonary tuberculosis, particularly those experiencing complications from the disease.
✕Less likely to help
Patients with non-pulmonary forms of tuberculosis or those who do not have active TB infections may not benefit from this research.
What this research studies
This research investigates the use of pro-apoptotic drugs, specifically navitoclax, to enhance the treatment of pulmonary tuberculosis (TB) by promoting the death of infected cells. The approach aims to reduce tissue damage and inflammation caused by TB, which can lead to chronic lung issues. By understanding how these drugs affect the immune response and bacterial clearance in the lungs, the research seeks to shorten TB treatment duration and prevent long-term lung damage. Patients may benefit from improved treatment outcomes and reduced side effects associated with traditional TB therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective TB treatments that reduce lung damage and improve long-term health outcomes for patients.
How similar studies have gone: Previous research has shown promising results with similar pro-apoptotic approaches in animal models, indicating potential for success in human applications.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Jain, Sanjay — Johns Hopkins University
- Study coordinator: Jain, Sanjay
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.